LivaNova overview and recent share moves

LivaNova (LIVN) has drawn investor attention after recent share price moves, with the stock showing double digit total returns over the past year, as well as solid gains over the past month and the past three months.

The recent 7-day share price return of 18.01%, alongside a 16.96% year-to-date share price return and a 60.94% 1-year total shareholder return, indicates that momentum has been building over both shorter and longer horizons.

If you are looking beyond LivaNova for other ideas in healthcare technology, this could be a good moment to scan 35 healthcare AI stocks

With LivaNova trading at $70.93, sitting about 14% below the average analyst price target and at an estimated 33% discount to intrinsic value, the key question is whether this reflects a potential valuation gap or a market that is already accounting for future growth expectations.

Most Popular Narrative: 10.4% Undervalued

The most followed narrative currently pegs LivaNova's fair value at $79.18 compared with the latest close around $70.93, framing the recent share price strength as still leaving room before that narrative value is reached.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Want to understand why this fair value sits above today's price? The narrative leans heavily on revenue expansion, margin rebuild, and a richer earnings multiple. Curious how those pieces fit together and what has to go right over the next few years for that math to hold?

Behind that headline number is a full earnings road map, including projected revenue growth, margin recovery from recent loss making levels, and a future P/E that implies a premium to the broader medical equipment peer group and current market multiples. The narrative also applies an 8.6% discount rate to translate those forecasts back into today's dollars, which is a key lever for how sensitive the $79.18 figure is to changes in growth or risk assumptions.

Result: Fair Value of $79.18 (UNDERVALUED)

However, this hinges on reimbursement remaining supportive and on new therapies clearing regulatory and safety hurdles without disruptions that could pressure revenue and margins.

Next Steps

With all of this in mind, does the current optimism around LivaNova match your own take on the numbers and assumptions being used? If you want to move quickly from headline story to hard evidence, spend a few minutes reviewing the 3 key rewards

Looking for more investment ideas?

Do not stop with a single stock. The best portfolios are built from a watchlist of different opportunities, and skipping this step can mean missing some of the market's most interesting setups.

• Target companies that combine quality with attractive pricing by scanning 51 high quality undervalued stocks for ideas that may warrant a closer look.
• Strengthen your focus on resilience by checking out the 72 resilient stocks with low risk scores and spotting businesses with more defensive profiles.
• Get ahead of the crowd by searching the screener containing 23 high quality undiscovered gems and finding candidates that are not yet widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.